Search

In Stock

Buy Crysvita (burosumab) Online

Crysvita (burosumab) is a human monoclonal antibody medication used to treat X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) in adults and children 6 months of age and older. It is the first and only FDA-approved treatment for XLH.

From $3,328.84

Clear
Compare
SKU:241914

Crysvita (burosumab) is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH). XLH is a rare genetic disorder that causes the body to lose too much phosphorus. Phosphorus is a mineral that is essential for strong bones and muscles. People with XLH have low levels of phosphorus in their blood and bones, which can lead to a number of health problems, including:

  • Rickets (softening and weakening of the bones) in children
  • Osteomalacia (softening and weakening of the bones) in adults
  • Muscle weakness
  • Pain in the bones and joints
  • Fatigue

Crysvita works by blocking the action of fibroblast growth factor 23 (FGF23), a hormone that causes the body to lose phosphorus. By blocking FGF23, Crysvita helps to increase and maintain phosphorus levels in the blood and bones. This can help to improve bone health, reduce pain and muscle weakness, and improve quality of life.

Crysvita is given as an injection under the skin (subcutaneous injection) once every two weeks. The dose of Crysvita is based on the patient’s weight and age.

Crysvita is generally safe and well-tolerated. The most common side effects are mild and go away on their own. These side effects can include:

  • Injection site reactions
  • Headache
  • Fatigue
  • Nausea
  • Constipation

In rare cases, Crysvita can cause more serious side effects, such as:

  • Allergic reactions
  • High levels of calcium in the blood
  • Jaw problems

Crysvita is a major breakthrough in the treatment of XLH. It is the first and only FDA-approved treatment that specifically targets the underlying cause of XLH. Crysvita has been shown to be effective in improving bone health, reducing pain and muscle weakness, and improving quality of life in people with XLH.

If you or your child has XLH, talk to your doctor about whether Crysvita is right for you.

Package

1 single-dose vial of 10 mg/mL, 1 single-dose vial of 20 mg/mL, 1 single-dose vial of 30 mg/mL

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Waylivra (volanesorsen) Online

$11,550.76
(0 Reviews)
DISEASE INDICATIONS: Familial chylomicronemia syndrome (FCS) MANUFACTURER: Akcea Therapeutics Ireland Limited USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Waylivra (volanesorsen) is a prescription medication used to treat adults with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. FCS is a rare genetic disorder that causes the body to produce too much of a type of fat called chylomicrons. Chylomicrons can build up in the blood and cause pancreatitis, a serious inflammation of the pancreas.

Buy Isturisa (osilodrostat) Online

From $1,818.17
(0 Reviews)
DISEASE INDICATIONS: Primary Biliary Cholangitis (PBC) MANUFACTURER: Novartis USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Isturisa (osilodrostat) is a cortisol synthesis inhibitor used to treat Cushing's syndrome, a condition in which the body produces too much of the hormone cortisol. It is approved by the US Food and Drug Administration (FDA) for adults with Cushing's disease, a type of Cushing's syndrome caused by a tumor on the pituitary gland, and for adults with endogenous Cushing's syndrome (ECS), a type of Cushing's syndrome caused by the body overproducing cortisol on its own.

Buy Zokinvy (lonafarnib) Online

From $31,401.66
(0 Reviews)
DISEASE INDICATIONS: Progeria MANUFACTURER: Eiger Biopharmaceuticals USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Zokinvy (lonafarnib) is a prescription medication used to treat Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL) in children aged 12 months and older. HGPS and PDPL are rare genetic disorders that cause premature aging.

Buy Oxlumo (lumasiran) Online

$64,110.43
(0 Reviews)
DISEASE INDICATIONS: Primary hyperoxaluria type 1 (PH1) MANUFACTURER: Alnylam Pharmaceuticals USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Oxlumo (lumasiran) is a prescription medicine used to treat primary hyperoxaluria type 1 (PH1) in children and adults. PH1 is a rare genetic disorder that causes the body to produce too much of a substance called oxalate. Oxaluria can cause kidney stones, damage to the kidneys and other organs, and even death.

Buy Leqvio (inclisiran) Online

$2,671.00
(0 Reviews)
DISEASE INDICATIONS: Hypercholesterolemia MANUFACTURER: Novartis USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Buy Evkeeza (evinacumab) Online

(0 Reviews)
DISEASE INDICATIONS: Hypercholesterolemia MANUFACTURER: Regeneron Pharmaceuticals, Inc. USAGE: Intravenous MEDICINE APPROVED BY: Food and Drug Administration (FDA) Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.

Buy Kerendia (finerenone) Online

From $618.20
(0 Reviews)
Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Back to Top
Product has been added to your cart